Xilio Therapeutics (XLO) Restructuring Costs (2024)
Xilio Therapeutics' (XLO) quarterly Restructuring Costs came in at -$41000.0 in Q3 2024, down 236.67% quarter-over-quarter from $30000.0 in Q2 2024.
Powered by 
Analysis
Xilio Therapeutics (XLO) Restructuring Costs (2024) Analysis & Trends
Xilio Therapeutics has disclosed Restructuring Costs across 1 years of filings, most recently posting -$41000.0 for Q3 2024.
- In Q3 2024, Restructuring Costs changed N/A year-over-year to -$41000.0; the TTM figure through Dec 2024 stood at $937000.0 (changed N/A YoY), while the FY2024 annual figure was $937000.0, changed N/A from the prior year.
- Restructuring Costs came in at -$41000.0 for Q3 2024 at Xilio Therapeutics, down from $30000.0 in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $948000.0 in Q1 2024 to a low of -$41000.0 in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Xilio Therapeutics | 174.55 Mn | 38.51 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2024 | -41,000.00 |
| Jun 30, 2024 | 30,000.00 |
| Mar 31, 2024 | 948,000.00 |